

Dear collaborators, partners, and members of the MoLBI community,

MoLBI continues to gather momentum as a leading translational cancer research platform, with growth in our live biobank, new collaborative studies, national infrastructure partnerships and continued progress towards first-in-human precision oncology trials.

337 tumours collected and growing: Thanks to the generosity of our patients, MoLBI has now collected 337 tumour specimens, an important milestone that reflects the remarkable support of our patients and the dedication of our neurosurgical, nursing, laboratory and research teams. Together, these milestones reflect MoLBI's vision of creating an integrated ecosystem that connects patients, biospecimens, genomics, engineering and early-phase clinical trials to accelerate precision oncology.

As the platform continues to grow, so too does our collaborative network. We are delighted that 2 new collaborative studies have received provisional approval through the MoLBI Steering Committee:

- **Brain Border Immunology in Brain Tumours**, led by Dr [Leon Smyth](#) (Group leader at Monash Biomedicine Discovery Institute studying the role meninges in defining neuroimmune interactions at the borders of the central nervous system).
- **Investigating Cellular Mechanisms Generating Epileptic Activities in the Human Brain**, led by Dr [Madhusoothanan Bhagavathi Perumal](#) (Neuroscience Physiology, Monash Biomedicine Discovery Institute).

These projects further expand the scientific opportunities through prospective collection of high-quality human biospecimens.

MoLBI contributes to national research infrastructure: We are also pleased that MoLBI has been included as part of the MRFF National Critical Research Infrastructure (NCRI) application led by the Translational Research Institute (Brisbane), in collaboration with Professor Kristen Radford and colleagues. The proposed Human Immune Model Facility (HIMF) aims to establish Australia's first coordinated national humanised mouse infrastructure, providing researchers with access to clinically relevant models for immunotherapy, vaccine and immune-targeted research. MoLBI will contribute through its expertise in translational cancer models and human tumour biospecimens.

MoLBI featured across Monash: Following our 250 tumour milestone, MoLBI has been featured in the Faculty of Medicine, Nursing and Health Sciences news, highlighting how the platform is accelerating translational cancer discoveries and creating new opportunities for precision medicine ([click here for the article](#)). The story was subsequently shared by the Faculty of Engineering, reflecting the increasingly multidisciplinary nature of the MoLBI platform and its collaborations across medicine, engineering and computational sciences ([click here for the LinkedIn article](#)).

First peer-reviewed publication arising from the MoLBI platform: Congratulations to Adrian Praeger and colleagues on publishing the first scientific paper acknowledging the MoLBI platform - "[Optimising surgical resection strategy in high-grade glioma: an evidence-informed, capability-aligned surgical framework for heterogeneous health systems](#)". Journal of Clinical Neuroscience (2026)". We look forward to many more publications arising from MoLBI-supported research over the coming years.

Supporting rapid genomic diagnostics: A major boost to our Clinical Genomics Laboratory has come through the generous donation of a high-performance computing system from Atturra, Dicker Data and Dell. This system will enable full implementation of our Oxford Nanopore sequencing platform, support rapid genomic analysis of brain tumours and bring us closer to real-time molecular profiling, even during surgery. A sincere thank you to Linda Biviano, Jane Murphy (left), and our consumer advocate Mark Norris (Mark's son and Tu – right) for making this possible.




Growing support for the CAM model: We are incredibly grateful to the Deegan Family Charitable Foundation for their generous donation to support development of the MoLBI chorioallantoic membrane (CAM) model. This funding will contribute towards the purchase of an ultrasound imaging system, allowing non-invasive assessment of tumour morphology, vascularity and growth. We were delighted that Peter Coombs, Shehani Fernando and the Monash Health team, demonstrated the exciting potential of ultrasound technology in CAM.

Clinical translation continues to progress: Significant progress has also been made towards translating our laboratory discoveries into first-in-human studies. Our Phase Zero brain cancer platform study was resubmitted to Human Research Ethics Committee on 22 July, addressing recommendations from the HREC, independent scientific review and special review meeting. Meanwhile, governance approval for our Providence off-the-shelf mRNA cancer vaccine program is entering its final stages, bringing us closer to treating our first patient through this exciting immunotherapy platform.

Consumer Corner: Our consumer advocates continue to play an integral role in the growth of MoLBI. Mark Norris facilitated our partnership with Blue Connections IT, and Sarah Tozer was instrumental in securing the generous Deegan Family Office donation.

We are incredibly grateful to every patient, clinician, scientist, consumer advocate, donor and collaborator who has contributed to the MoLBI journey. Together we are building a platform that we hope will transform how translational cancer research is conducted and, ultimately, improve outcomes for patients with brain cancer and other solid tumours.

With best wishes,



Dr Gwo Yaw Ho
Founder and Chair, Monash Live-Biobanking



Professor Justin Moore
Director of Neurosurgery, Monash Health